A pilot study of evap/abv chemotherapy in 25 newly diagnosed children with hodgkin's disease

ABSTRACT Twenty five children with newly diagnosed Hodgkin's disease were clinically staged and treated with a chemotherapy protocol designed to reduce delayed toxicity. Four patients

without macroscopic residual disease after biopsy received three cycles of hybrid EVAP/ABV. All remain in CR 31-46 months from diagnosis. One other developed fever and rash considered to be

due to Ara-C and was treated with MOPP. Twenty patients had macroscopic residual disease after biopsy and were treated with two cycles of EVAP alone and reassessed with imaging and gallium

scans. Twelve achieved CR, seven PR and one was not evaluable. Patients in CR were subsequently treated with 2-4 cycles of hybrid EVAP/ABV, while those in PR received 3-4 cycles. At a median

follow up of 37 months the overall survival was 100%, relapse free 79% and treatment failure free 60%. Eight patients had mediastinal widening > 1/3 thoracic width. At the completion of

the protocol five achieved CR, two PR and one was withdrawn from study at investigator preference. One patient has subsequently relapsed. Of the evaluable ten patients without a mediastinal

presentation all achieved CR but three relapsed at 10, 13 and 18 months from diagnosis. Patients who achieved a PR only, relapsed or were withdrawn from study have been salvaged with MOPP or

Ch1VPP chemotherapy. Access through your institution Buy or subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution

Subscribe to this journal Receive 24 print issues and online access $259.00 per year only $10.79 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full

article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs *

Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS FOLLOW-UP OF THE GHSG HD16 TRIAL OF PET-GUIDED TREATMENT IN EARLY-STAGE FAVORABLE HODGKIN LYMPHOMA Article Open access 16

October 2023 RADIOTHERAPY IN YOUNGER PATIENTS WITH ADVANCED AGGRESSIVE B-CELL LYMPHOMA—LONG-TERM RESULTS FROM THE PHASE 3 R-MEGACHOEP TRIAL Article Open access 27 March 2024 RITUXIMAB AS

ADJUNCTIVE THERAPY TO BEAM CONDITIONING FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN HODGKIN LYMPHOMA Article 01 February 2022 AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Australian and New

Zealand Children's Cancer Study Group, Royal Children's Hospital, Melbourne H Ekert Authors * H Ekert View author publications You can also search for this author inPubMed Google

Scholar * T Fok View author publications You can also search for this author inPubMed Google Scholar * L Dalla-Pozza View author publications You can also search for this author inPubMed 

Google Scholar * K Waters View author publications You can also search for this author inPubMed Google Scholar * P Smith View author publications You can also search for this author inPubMed

 Google Scholar * L White View author publications You can also search for this author inPubMed Google Scholar RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS

ARTICLE Ekert, H., Fok, T., Dalla-Pozza, L. _et al._ A pilot study of EVAP/ABV chemotherapy in 25 newly diagnosed children with Hodgkin's disease. _Br J Cancer_ 67, 159–162 (1993).

https://doi.org/10.1038/bjc.1993.28 Download citation * Issue Date: 01 January 1993 * DOI: https://doi.org/10.1038/bjc.1993.28 SHARE THIS ARTICLE Anyone you share the following link with

will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt

content-sharing initiative